CASE CCC IN THE NEWS
Cleveland Clinic Study Shows no Increased Risk of MDS After Radiation for Prostate Cancer
The Plain Dealer - Feb 27, 2014
A study published Wednesday in the Journal of the National Cancer Institute is providing encouraging news to prostate cancer patients who need radiation therapy. The findings of the study, conducted at the Cleveland Clinic, shows that those men have no greater risk for developing myelodysplastic syndromes, or MDS, than the general population.....For so long, it has been accepted at face value that if a patient had been previously treated for prostate cancer, and then years later developed MDS, it was a cause-and-effect relationship, said Dr. Mikkael Sekeres, director of the Leukemia Program at the Clinic's Taussig Cancer Institute, member of the Case Comprehensive Cancer Center, and the study's lead author.
Fever In, Fever Out –Improving Quality In Emergency Room Care of Patients with Fever and Neutropenia
Oncology Times - Feb 24, 2014
Dr. Mikkael Sekeres, director of the Leukemia Program at the Clinic's Taussig Cancer Institute and member of the Case Comprehensive Cancer Center, discusses improving quality in emergency room care of patients with fever and neutropenia.
Gland-Sparing RT Keeps Saliva Flowing
MedPage Today - Feb 24, 2014
Patients with oropharyngeal cancer retained salivary function, with no apparent increased risk of disease spread, with gland-sparing radiation therapy, data from two studies showed...The studies reflect the progress that has occurred in the treatment of head and neck cancer, which has placed more emphasis on patient-reported outcomes, said Mitchell Machtay, MD, of University Hospitals Case Medical Center and Case Comprehensive Cancer Center in Cleveland.
Patients Blame H&N Therapy for Lasting Speech Issues
MedPage Today - Feb 23, 2014
Patients with oropharyngeal cancer reported significant voice and speech impairment for up to 2 years after chemoradiation therapy, but most of their doctors saw no evidence of it, data from a prospective study showed...Press briefing moderator Mitchell Machtay, MD, said he found the study eye opening. "If you looked at radiation dose to larynx, not the area where the tumor was, I was struck by how doses of 20 to 30 Gy, which we don't normally consider as very toxic high doses that can damage the voicebox, still caused a fair amount of damage," said Machtay, of University Hospitals Case Medical Center and the Case Comprehensive Cancer Center in Cleveland.
Dr. Paul Tesar Recognized with Professorship of Innovative Cancer Therapeutics
Dr. Paul Tesar was appointed the Dr. Donald and Ruth Weber Goodman Professorship of Innovative Cancer Therapeutics at a ceremony held on Thursday, February 27, 2014.
Originally from Cleveland, Dr. Tesar is a CWRU alumnus, receiving his undergraduate degree in biology under the mentorship of Dr. Stephen Haynesworth. Dr. Tesar's potential was evident early on, attracting the notice of the National Institutes of Health, which bestowed on him a scholarship to complete his PhD at the University of Oxford.
Building on the work of the 2012 Nobel Prize winners in Medicine who discovered how to turn skin cells into stem cells, Dr. Tesar's lab took this landmark discovery even further and discovered how to transform skin cells directly into brain cells, or specifically, oligodendrocytes.
With Dr. Tesar's focus on the cellular and molecular processes that contribute to normal neural development, he is well positioned to make discoveries that impact an array of patients, from individuals facing brain cancer, to patients with Multiple Sclerosis, Cerebral Palsy, or children with leukodystrophies.
The late Donald Goodman, a CWRU alumnus from the School of Dental Medicine, was inspired to create this professorship in Cancer Research Innovation because of a seemingly miraculous treatment he received that cleared him of an aggressive form of leukemia, just 12 days after his first treatment.
Madabhushi/CCIPD Team Wins Accolades at SPIE Medical Imaging 2014
The lab of Cancer Center member Dr. Anant Madabhushi and the Center of Computational Imaging and Personalized Diagnostics (CCIPD) won four awards for papers presented at the SPIE Medical Imaging 2014 meeting in San Diego, CA, February 15-19, 2014.
- Geert Litjens, former visiting graduate student at CCIPD, was awarded runner-up for the Robert F. Wagner Best Student paper for his manuscript Distinguishing benign confounding treatment changes from residual prostate cancer on MRI following laser ablation. Dr. Madabhushi, Associate Professor of Biomedical Engineering, was the senior author on this study, which also included Drs. Robin Elliot from the Case Institute of Pathology and Dr. Satish Viswanath, research assistant professor, Case BME.
- Eileen Hwang, former visiting undergraduate student at CCIPD, won the Cum Laude Award for her poster Spectral embedding based registration (SERg) aligning multimodal prostate histology and MRI. Dr. Madabhushi was the senior author on this study that also included post-doctoral fellow Dr. Mirabela Rusu in Case BME.
- Dr. Pallavi Tiwari, research assistant professor at Case BME, won an Honorable mention Award for her poster Computerized image analysis for texture descriptors in multi-parametric MRI to distinguish recurrent brain tumors from radiation necrosis. Dr. Madabhushi was the senior author on this study that also included Prateek Prasanna, graduate student at Case BME, along with Drs. Mark Cohen, Leo Wolansky, and CCC members Drs. Lisa Rogers and Andrew Sloan.
- Dr. Pallavi Tiwari, research assistant professor at Case BME, and Dr. Madabhushi also won the Cum Laude Award for her poster Identifying MRI markers to evaluate early treatment-related changes post-laser ablation for cancer pain management. This work was done jointly with Dr. Shabbar Danish, MD at Rutgers University.
Case-Coulter Translational Research Partnership
The Case-Coulter Translational Research Partnership (CCTRP) is accepting letters of intent for 2014. The purpose of CCTRP funding is to support collaborative translational research projects that address unmet or poorly met clinical needs. CCTRP seeks to reduce the market risk of promising new clinical products arising from the research programs of BME and other Case faculty.
LOI Deadline: March 28
Skin Disease Research Center
The Skin Disease Research Center (SDRC) sponsors innovative research through its Pilot and Feasibility (P&F) Program. The SDRC plans to support one new P&F project for funding for one or two years with an annual budget of $25,000. Projects are supported with the understanding that the PI will subsequently apply for NIH or equivalent funding using preliminary data acquired during the P&F project period. Funding for the second year is contingent upon satisfactory progress and submission of a progress report.
Deadline: March 31
Request for Proposals for Case CCC Funding for Pilot/Phase I Clinical Trials
The Case CCC is encouraging investigators to submit Letters of Intent (LOI) for Early Phase Clinical Research Support (EPCRS) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Priority will be given to trials which are developed jointly between UH and CCF with planned accrual at both institutions. (See revised NCI Cancer Center Support Grant EPCRS guidelines, page 43, Section 2.12). Please submit LOIs to Katarzyna Karelus, Case CCC Clinical Research Office, email@example.com, 216.844.4176.
LOI deadline: April 15
The Discovery Fast Track Challenge from the Discovery Partnerships with Academia (DPAc) group at GlaxoSmithKline (GSK) is now open for submissions. This is an outstanding opportunity to work with GSK to discover new pharmacologically active molecules via High Throughput Screening (HTS) and/or Encoded Library Technology (ELT). For successful applicants, this will help drive their research forward –and could lead to a partnership with GSK for the development of a new medicine. Applications require approval from the CWRU Technology Transfer Office. Please contact Stephanie Weidenbecher at firstname.lastname@example.org or 216.368.6191.
Deadline: May 16
Brian Werbel Memorial Fund
Applications are currently being accepted for summer cancer research fellowship fundingWerbel2014, provided by the Brian Werbel Memorial Fund. This fund was established in 2007 at University Hospitals Case Medical Center, and is dedicated to providing summer fellows an opportunity to focus on cancer research, with the ultimate goal to aid in curing cancer. Brian's hope was to find a cure for cancer – to make a difference in the world, just as he made a difference in the lives of everyone he touched. Applicants must be conducting cancer research with a Case Comprehensive Cancer Center member. Awardees are required to attend the Annual Golf Outing Event, typically held in July.
Deadline: April 25
SAVE THE DATE
Retreat: Engaging in Cultural Competence through Awareness, Knowledge and Action
Please mark your calendars for Thursday, March 13 from 2-5 pm to join the Case Comprehensive Cancer Center and the Case Center for Reducing Health Disparities as they explore issues related to cultural competence. Extend your knowledge and raise your awareness about the dynamic variety of people and communities the Case CCC serves. This retreat will feature a keynote address by Dr. Sonja Harris-Haywood, and will provide perspective on the growing need to be culturally competent and facilitate the impact of cultural beliefs within the health care setting, specifically in research.
The retreat is intended for investigators, research nurses, regulatory coordinators, outreach and training and education personnel. Pre-registration by Friday, March 7 is required. Please direct any questions to Katarzyna Karelus at 216.844.4176 or email@example.com.